Skip to main content

Table 3 Summarized HRs of overall and subgroup analyses for DFS

From: Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients

Stratified analysis Study(N) HR Z P Heterogeneity
I2 P Estimated method
DFS 21 1.894(1.456–2.463) 4.76 < 0.001 78.30% < 0.001 Random-effect
Subgroup analysis for DFS
Publication year
 Early year(~ 2007) 6 1.428(0.992–2.055) 1.92 0.055 62.10% 0.022 Random-effect
 Later year(2007~ 2016) 15 2.237(1.54–3.249) 4.23 < 0.001 72.00% < 0.001 Random-effect
Region
 Europe 3 1.023(1.005–1.041) 2.51 0.012 53.40% 0.117 Fixed-effect
 America 4 1.559(1.155–2.105) 2.9 0.004 8.40% 0.351 Fixed-effect
 Asia 14 2.673(2.096–3.409) 7.92 < 0.001 25.60% 0.179 Fixed-effect
Histological type
 SCLC
 NSCLC 21 1.894(1.456–2.463) 4.76 < 0.001 78.30% < 0.001 Random-effect
 ADC 9 3.186(1.797–5.650) 3.96 < 0.001 62.10% 0.007 Random-effect
 SQC 2 1.022(1.004–1.04) 2.42 0.015 0.00% 0.774 Random-effect
Sample size
  < 100 7 2.455(1.392–4.330) 3.10 < 0.001 20.30% 0.28 Fixed-effect
  > 100 14 1.770(1.340–2.338) 4.02 < 0.001 82.80% < 0.001 Random-effect
Cutoff value
 L(< 20%) 12 2.783(2.141–3.619) 7.64 < 0.001 25.30% 0.196 Fixed-effect
 H(≥20%) 6 1.514(1.243–1.844) 4.12 < 0.001 19.40% 0.287 Fixed-effect
Estimated method
 Survival curve 2 1.595(1.053–2.416) 2.21 0.027 52.60% 0.146 Fixed-effect
 HR(univariate) 6 2.126(1.156–3.909) 2.43 0.015 67.40% 0.009 Random-effect
 HR(multivariate) 13 1.892(1.328–2.698 3.53 < 0.001 79.90% < 0.001 Random-effect